• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Can CBD Work for PTSD?

Can CBD Work for PTSD?

September 25, 2022
Sin Yan Lo, PMHNP-BC
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Sin Yan Lo, PMHNP-BC. Ms. Lo, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Bolsoni LI et al, Psychopharmacology (Berl) 2022;239(5):1499–1507

STUDY TYPE: Randomized double-blind, placebo-controlled trial

Marijuana contains close to 100 cannabinoids. Among them, tetrahydrocannabinol (THC) is responsible for marijuana’s psychotogenic and rewarding effects, while cannabidiol (CBD) has some evidence to reduce psychosis and anxiety. Patients often take CBD as an oral supplement (CBD oil or gummies), and it is available as a prescription (Epidiolex) for rare forms of epilepsy. This study aimed to see if CBD can soothe symptoms of PTSD and disrupt memory consolidation of the trauma.

The double-blind trial randomized 33 subjects with PTSD to take either CBD or placebo while undergoing exposure exercises related to past trauma. Patients with a history of substance use or psychiatric disorders other than anxiety and depression were excluded. There were three total exposure sessions, each given one week apart. 

During the exposure, the subjects listened to a 90-second recording of their traumatic experience and then imagined the trauma for 30 seconds (they recorded the 90-second narrative during the first session). The treatment was only given in the second exposure session, where subjects received either CBD 300 mg or placebo before undergoing the exposure. The intent was to test whether CBD could reduce PTSD symptoms after the exposure and whether the benefits, if any, persisted over the next week.

Symptoms were measured before and after the exposure. The primary outcome was change on a visual-analogue scale of anxiety, sedation, cognitive impairment, and discomfort. Secondary outcomes included the State-Trait Anxiety Inventory, a self-reported PTSD scale, and physiologic measures of blood pressure, heart rate, and salivary cortisol.

Those who took CBD reported improvement in cognitive symptoms (feeling capable, perceptive, better able to reason, physically agile, clear-headed, sociable, and resilient), and the effects were sustained for the week after taking it. However, it did not help with anxiety, alertness, or discomfort after recall of the trauma. There were no significant changes in blood pressure, heart rate, or salivary cortisol.

The main limitation here is the fact that the researchers used multiple tests without correcting for multiple comparisons. The sample size was also small, and comorbidities were not distributed evenly between the groups despite randomization. 

CARLAT TAKE

The study provides some reassurance that CBD oil does not worsen and may improve PTSD, but the methodological flaws mean we’re not ready to endorse its use.


General Psychiatry
KEYWORDS anxiety cannabidiol insomnia ptsd
Sin Yan Lo, PMHNP-BC

More from this author
www.thecarlatreport.com
Issue Date: September 25, 2022
SUBSCRIBE NOW
Table Of Contents
A Diet for ADHD
Understanding the Varieties of Depression
The Benzodiazepine-Stimulant Combo: What Could Go Wrong?
Treatment-Resistant Depression
Can CBD Work for PTSD?
Aripiprazole in Depression: The Right Dose
A Single Prescriber Reduces Risk of Overdose in Patients on Opioid and Benzodiazepine
CME Post-Test - Depression, TCPR, October/November 2022
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.